Home healthcare provider Addus HomeCare (NASDAQ: ADUS) will be reporting earnings this Monday afternoon. Here’s what to expect.
Addus HomeCare met analysts’ revenue expectations last quarter, reporting revenues of $373.1 million, up 25.6% year on year. It was a mixed quarter for the company, with a beat of analysts’ EPS estimates.
Is Addus HomeCare a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Addus HomeCare’s revenue to grow 8.4% year on year, slowing from the 20.3% increase it recorded in the same quarter last year.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Addus HomeCare has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at Addus HomeCare’s peers in the senior health, home health & hospice segment, some have already reported their Q1 results, giving us a hint as to what we can expect. BrightSpring Health Services delivered year-on-year revenue growth of 25.6%, beating analysts’ expectations by 6.3%, and Chemed reported revenues up 1.6%, topping estimates by 1.2%. Chemed traded up 10% following the results.
Read our full analysis of BrightSpring Health Services’s results here and Chemed’s results here.
There has been positive sentiment among investors in the senior health, home health & hospice segment, with share prices up 6% on average over the last month. Addus HomeCare is up 6.4% during the same time and is heading into earnings with an average analyst price target of $139.46 (compared to the current share price of $99.44).
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
